Galapagos Extends by $1M siRNA-Based Target-Validation Deal With Cystic Fibrosis Foundation | GenomeWeb
NEW YORK (GenomeWeb News) — Galapagos has extended by 15 months and €800,000 ($1 million) a two-year agreement with Cystic Fibrosis Foundation Therapeutics to use its siRNA and cDNA collections to develop new treatments for cystic fibrosis, the company said today.
 
Galapagos said its BioFocus DPI division is using its SilenceSelect adenoviral library to design assays that can identify and validate potential targets that could be the “basis for the development of new medicines.”   
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.